8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2008

Shire Limited

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0484822

(Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

     Shire Limited has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibit is filed herewith:

99.01                Press Release dated September 8, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE LIMITED
By:	/s/ A C Russell
	Name:   Angus Russell
	Title:     Chief Executive Officer

Dated: September 8, 2008

EXHIBIT INDEX
Number	Description
99.01	Press Release dated September 8, 2008

EX-99.1

Exhibit 99.01

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

Basingstoke, UK and Philadelphia, US – September 8, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire Limited

2.   Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):

3.   Full name of person(s) subject to the notification obligation:	Legal & General Group Plc (L&G) Legal & General Investment Management Limited (LGIM)
4.   Full name of shareholder(s) (if different from 3.):	Legal & General Assurance (Pensions Management) Limited (PMC)
5.   Date of the transaction (and date on which the threshold is crossed or reached if different):	4 September 2008
6.   Date on which issuer notified:	5 September 2008
7.   Threshold(s) that is/are crossed or reached:	Below 5% (Group) Below 5% (LGIM) From 5% - 4% (L&G)
8.   Notified details:

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

A: Voting rights attached to shares

Class/type of shares  if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
ORD GBP 0.05	31,053,995 (LGIM)	31,053,995 (LGIM)	Below 5% (LGIM)
ORD GBP 0.05	28,039,788 (ORD) (L&G)	28,039,788 (ORD) (L&G)	23,985,756	23,985,756		4.28
ADR	7,299 (ADR)	21,897 (ADR)	7,299	21,897		0.003

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date	Exercise/Conversion Period/ Date	Number of voting rights that may be acquired if  the instrument is exercised/converted	% of voting rights

Total (A+B)
Number of voting rights	% of voting rights
24,007,653 (L&G)	4.28 (L&G)
Below 5% (LGIM)

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) (Below 5%)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)  (Below 5%)

Legal & General Investment Management Limited (Indirect) (LGIM) (Below 5%)

Legal & General Group Plc (Direct) (L&G) (24,007,653 – 4.28 % = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct)  (LGIMHD) (21,131,760 –3.77 % = PMC)	Legal & General Insurance Holdings Limited (Direct) (LGIH)
Legal & General Assurance (Pensions Management) Limited  (PMC) (21,131,760 –3.77 % = PMC)	Legal & General Assurance Society Limited  (LGAS & LGPL)
	Legal & General Pensions Limited (Direct)  (LGPL)

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Proxy Voting:

10.   Name of the proxy holder:	N/A
11.   Number of voting rights proxy holder will cease to hold:	N/A
12.   Date on which proxy holder will cease to hold voting rights:	N/A

13.   Additional information:	Notification using the total voting rights figures of 559,980,974
14.   Contact name:	Helen Lewis (LGIM)
15.   Contact telephone number:	020 3124 3851

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX